The Clinical Core provides both services and expertise and has a strong training component for cystic fibrosis (CF) research. The services focus on regulatory support, and study design and conduct support. We serve as a local, National and International resource to collaborators for advanced clinical trial design and conduct, biostatistical and epidemiologic methods and comparative effect research methods including cost-effectiveness analysis. The Core supports the central aims of the UW Cystic Fibrosis Research and Translation Center (CFRTC): to use highly effective modulator therapy (HEMT) initiation to discover novel aspects of cystic fibrosis (CF) pathophysiology, define the clinical manifestations and best treatment approaches for the ?new? disease that CF will become, and perform basic and translational research on disease aspects that persist despite HEMT. Further, the CC fosters collaboration across the CFRTC biomedical cores to enhance translational research through the sharing of existing and development of expanded human and bacterial repositories linked to clinical databases that enable development of improved assays and clinical outcome measures. We are well positioned to continue to advance novel therapeutics through the drug development pipeline and transition to major studies in CF that focus on improving our understanding of the disease in the setting of advancing therapeutics ? specifically HEMT that will forever change the clinical landscape in CF.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK089507-11
Application #
9982662
Study Section
Special Emphasis Panel (ZDK1)
Project Start
2010-08-07
Project End
2025-05-31
Budget Start
2020-08-15
Budget End
2021-05-31
Support Year
11
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Seattle Children's Hospital
Department
Type
DUNS #
048682157
City
Seattle
State
WA
Country
United States
Zip Code
98105
Kang, Inkyung; Chang, Mary Y; Wight, Thomas N et al. (2018) Proteoglycans as Immunomodulators of the Innate Immune Response to Lung Infection. J Histochem Cytochem 66:241-259
Guimbellot, Jennifer; Solomon, George M; Baines, Arthur et al. (2018) Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations. J Cyst Fibros :
Goss, Christopher H; Sykes, Jenna; Stanojevic, Sanja et al. (2018) Comparison of Nutrition and Lung Function Outcomes in Patients with Cystic Fibrosis Living in Canada and the United States. Am J Respir Crit Care Med 197:768-775
Ramos, Kathleen J; Somayaji, Ranjani; Nichols, David P et al. (2018) Comparative Effectiveness Research in Pediatric Respiratory Disease: Promise and Pitfalls. Paediatr Drugs 20:1-7
Gharib, Sina A; McMahan, Ryan S; Eddy, William E et al. (2018) Transcriptional and functional diversity of human macrophage repolarization. J Allergy Clin Immunol :
Evanko, Stephen P; Chan, Christina K; Johnson, Pamela Y et al. (2018) The biochemistry and immunohistochemistry of versican. Methods Cell Biol 143:261-279
Kroken, Abby R; Chen, Camille K; Evans, David J et al. (2018) The Impact of ExoS on Pseudomonas aeruginosa Internalization by Epithelial Cells Is Independent of fleQ and Correlates with Bistability of Type Three Secretion System Gene Expression. MBio 9:
Heltshe, Sonya L; West, Natalie E; VanDevanter, Donald R et al. (2018) Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF. Contemp Clin Trials 64:35-40
Matamouros, Susana; Hayden, Hillary S; Hager, Kyle R et al. (2018) Adaptation of commensal proliferating Escherichia coli to the intestinal tract of young children with cystic fibrosis. Proc Natl Acad Sci U S A 115:1605-1610
Heltshe, Sonya L; Taylor-Cousar, Jennifer L (2018) Let's talk about sex: Behaviors, experience and health care utilization in young women with CF. J Cyst Fibros 17:5-6

Showing the most recent 10 out of 222 publications